Delivery Order SPE2DR25D2218-SPE2DR26FX5E9
Award Date 3/16/26
Potential Completion Date 4/6/26
Potential Value $33K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a delivery order to AmerisourceBergen Drug Corp on February 6, 2026, for hyperimmune rabies immunoglobulin (HYPERRAB 300 UNIT/ML, 5ML vials) with a ceiling value of $27,509.16. Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of March 2, 2026. The delivery order was issued under the DLA Troop Support Medical IDC, a single-award indefinite delivery contract valued at up to $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $3,467.48 to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. The order, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by December 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a competitive procurement under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $8,668.70 to AmerisourceBergen Drug Corp on December 29, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This competitive, firm fixed-price delivery order is scheduled for completion by January 21, 2026, with performance at the contractor's Conshohocken, Pennsylvania location. The award carries no set-aside designation, indicating it was competed among qualified vendors in the open market....
- The Defense Logistics Agency awarded a $33,547 delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of HYPERRAB 300 units/ml, a rabies immunoglobulin product. The contract is a firm fixed-price delivery order with an ultimate completion date of December 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to meet...
- The Defense Logistics Agency issued a $9,894.60 delivery order to AmerisourceBergen Drug Corp on March 13, 2026, for HYPERRAB 300 unit/mL vial 5mL pharmaceutical product, with ultimate completion on April 3, 2026. The order is issued under the DLA Troop Support Medical Indefinite Delivery Contract (IDC), a $999,999,999 vehicle through December 2026 that supplies pharmaceutical products and medical commodities to support military healthcare programs worldwide. Place of performance is...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of HYPERRAB 300 Unit/mL (rabies immune globulin) with a ceiling value of $9,894.60. This is a firm fixed price delivery order with an ultimate completion date of January 6, 2026, issued under a non-set-aside competitive procurement. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,012.76 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of December 10, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the...
- The Defense Logistics Agency issued an $18,898.32 delivery order to AmerisourceBergen Drug Corp on March 3, 2026, for globulin rabies immunoglobulin, with an ultimate completion date of March 24, 2026. The order is issued under the DLA Troop Support Medical Indefinite Delivery Contract (valued at up to $999,999,999 through December 2026), which provides pharmaceutical and medical supply support globally for military healthcare programs. Place of performance is Conshohocken, Pennsylvania. Pricing...
- The Defense Logistics Agency awarded a $16,491 delivery order to AmerisourceBergen Drug Corp on January 22, 2026, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This competitively awarded, firm fixed-price delivery order is set to be completed by February 12, 2026, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency issued a $7,874.30 delivery order to AmerisourceBergen Drug Corp on March 6, 2026, for globulin rabies immunoglobulin with an ultimate completion date of March 26, 2026. The order is issued under the DLA Troop Support Medical IDC (SPE2DX), a $999,999,999 indefinite delivery contract through December 2026 that supplies pharmaceutical products and medical supplies globally to support military healthcare programs. Place of performance is Conshohocken, PA. Pricing is...